Abbott Introduces RealTime Molecular Assay in Europe for Detection of HPV Infection
- Details
- Category: Abbott
European clinicians will have a new weapon to combat cervical cancer with the introduction of Abbott Molecular's real-time polymerase chain reaction (PCR) based diagnostic test for human papillomavirus (HPV). The CE-marked assay can identify patients infected with specific viral genotypes known to pose the highest risk for progression to cervical cancer.
Genzyme and Isis Begin New Clinical Trials of Mipomersen
- Details
- Category: Genzyme
Genzyme Corp. (Nasdaq: GENZ) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) have begun two new studies of mipomersen, a novel lipid-lowering drug in late-stage development, and a third is currently screening patients. These three trials will provide additional data on mipomersen in high-risk patient populations.
GlaxoSmithKline successfully completes tender offer for shares of Genelabs Technologies, Inc.
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline plc [LSE/NYSE: GSK] has announced the successful completion of the tender offer by its wholly-owned subsidiary Gemstone Acquisition Corporation for shares of common stock of Genelabs Technologies, Inc. [Nasdaq: GNLB].
U.S. Patent and Trademark Office Accepts Pfizer's Reissue Application on Lipitor
- Details
- Category: Pfizer
Pfizer Inc announced today that the U.S. Patent & Trademark Office has issued a "Notice of Allowance" accepting the company's application to correct the technical defect in the '995 enantiomer patent for atorvastatin calcium, the salt form of atorvastatin sold as Lipitor.
Novo Nordisk and VLST Corporation announce collaboration agreement
- Details
- Category: Novo Nordisk
Novo Nordisk and VLST Corporation, a Seattle-based biotechnology company focused on the development of therapeutics for autoimmune and inflammatory disorders, have entered into an exclusive, worldwide collaboration agreement to develop therapeutic targets utilising VLST's technology platform in the fields of autoimmune and inflammatory disorders.
GlaxoSmithKline to cease providing corporate political contributions
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline has announced a new global policy to voluntarily stop all corporate political contributions. In the past, GSK - in common with many companies and in full compliance with local laws - has made a number of corporate contributions in countries such as the US and Canada. GSK's new policy will ensure that no such contributions will be made in the future.
Glivec shows significant benefit for gastrointestinal stromal tumor (GIST) patients
- Details
- Category: Novartis
Glivec® (imatinib) has been approved by the US Food and Drug Administration (FDA) for the post-surgery treatment of adult patients following complete surgical removal of Kit (CD117)-positive gastrointestinal stromal tumors (GIST).
More Pharma News ...
- AstraZeneca and MAP Pharmaceuticals Announce Worldwide Collaboration
- First and Only Fibrate Indicated for Use in Combination With a Statin for Cholesterol Management
- Bayer innovations provide solutions for the global challenges of the future
- Roche and Axiogenesis Enter into Co-Development and Marketing Agreement
- Pfizer and Sigma-Tau Announce an Agreement to Market a Potential New Treatment for Malaria
- AstraZeneca and Bristol-Myers Squibb Announce Expansion of Worldwide Collaboration
- GSK analysis shows Seretide/Advair is a well tolerated and effective medicine